Big pharma stocks slide by up to 7% in global sell-off

6 February 2018

Big pharma was not immune to the sell-off of shares that has spread to markets globally after hitting Wall Street on Monday.

The cause for the Dow Jones losses is believed to be fears that US interest rates might rise more quickly than expected to tackle inflation resulting from strong wage growth.

Looking at closing US prices on Monday, The Street noted that some pharma and biotech stocks outpaced the big declines in the broader stock market. The Dow ended the day down 1,175.21 points, or 4.6%. The broader S&P 500 finished 4.1%, or 113.19 points, lower.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK